PLGA from PolySciTech used in development of cell membrane-derived nanoparticle for cancer immunotherapy

The human immune system is extremely powerful though most forms of cancer have developed ways to evade it. Researchers at University of Texas at Arlington and Southwestern Medical Center Used PLGA (Cat# AP082) from PolySciTech Division of Akina, Inc (www.polyscitech.com) to create particles with HER2 specific coating. These particles localized in tumor areas and delivered cisplatin. This research holds promise to improve therapy against cancer in the future. Read more: Yaman, Serkan, Harish Ramachandramoorthy, Priyanka Iyer, Uday Chintapula, Tam Nguyen, Manoj Sabnani, Tanviben Kotadia et al. "Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles." Bioactive Materials 34 (2024): 422-435. https://www.sciencedirect.com/science/article/pii/S2452199X23004309

“Highlights: Membrane coating aids camouflage Nanoparticle delivery. CAR-T based receptor increases targeting towards Non-small cell lung cancer. Paves new strategy for Syngenic cancer therapeutics. Abstract: Cell membrane-derived nanoparticles (NPs) have recently gained popularity due to their desirable features in drug delivery such as mimicking properties of native cells, impeding systemic clearance, and altering foreign body responses. Besides NP technology, adoptive immunotherapy has emerged due to its promise in cancer specificity and therapeutic efficacy. In this research, we developed a biomimetic drug carrier based on chimeric antigen receptor (CAR) transduced T-cell membranes. For that purpose, anti-HER2 CAR-T cells were engineered via lentiviral transduction of anti-HER2 CAR coding lentiviral plasmids. Anti-HER2 CAR-T cells were characterized by their specific activities against the HER2 antigen and used for cell membrane extraction. Anti-cancer drug Cisplatin-loaded poly (D, l-lactide-co-glycolic acid) (PLGA) NPs were coated with anti-human epidermal growth factor receptor 2 (HER2)-specific CAR engineered T-cell membranes. Anti-HER2 CAR-T-cell membrane-coated PLGA NPs (CAR-T-MNPs) were characterized and confirmed via fluorescent microscopy and flow cytometry. Membrane-coated NPs showed a sustained drug release over the course of 21 days in physiological conditions. Cisplatin-loaded CAR-T-MNPs also inhibited the growth of multiple HER2+ cancer cells in vitro. In addition, in vitro uptake studies revealed that CAR-T-MNPs showed an increased uptake by A549 cells. These results were also confirmed via in vivo biodistribution and therapeutic studies using a subcutaneous lung cancer model in nude mice. CAR-T-MNPs localized preferentially at tumor areas compared to those of other studied groups and consisted of a significant reduction in tumor growth in tumor-bearing mice. In Conclusion, the new CAR modified cell membrane-coated NP drug-delivery platform has demonstrated its efficacy both in vitro and in vivo. Therefore, CAR engineered membrane-coated NP system could be a promising cell-mimicking drug carrier that could improve therapeutic outcomes of lung cancer treatments.”

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/





NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

BPR (Biotech Pharma Research) Conference (April 10, 2024, KPTC West Lafayette, IN) is a​ free ​scientific/​networking conference hosted by Akina (http://bprconference.com/​).